Lupin's share price rose as Nomura maintained a positive rating amid patent litigation.The United States District Court ruled in favor of Astellas Pharma in a patent infringement case against Lupin's generic product.Nomura believes there is a strong possibility of generics prevailing in the litigation.Lupin's stock rose by 1.43% to Rs 1,961.90 apiece.